Peter Heerma compensation by year
Travere Therapeutics Summary Compensation Table · all 7 fiscal years held| Component | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Salary | $100,000 | $407,667 | $421,685 | $453,190 | $487,167 | $503,750 | $527,917 |
| Bonus | $87,500 | $87,500 | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $393,750 | $278,280 | $403,200 | $761,200 | $604,800 | $299,155 | $583,110 |
| Option awards | $695,130 | $508,217 | $791,194 | $538,929 | $656,747 | $342,258 | $738,247 |
| Non-equity incentive | $46,250 | $232,050 | $253,368 | $239,400 | $240,100 | $353,500 | $397,500 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $2,648 | $18,576 | $11,529 | $13,028 | $15,100 | $14,697 | $14,977 |
| Total | $1,325,278 | $1,532,290 | $1,880,976 | $2,005,747 | $2,003,914 | $1,513,360 | $2,261,751 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Travere Therapeutics, Inc. DEF 14A filed April 6, 2026, accession 0001438533-26-000027, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Travere Therapeutics, Inc. filed document, accession 0001438533-26-000027. Every figure is read from that document and cited to the page and table it appears in. Filed April 6, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 21,500 | $821,515 | — |
| RSU | 18,750 | $716,438 | — |
| RSU | 10,125 | $388,876 | — |
| RSU | 8,500 | $324,785 | — |
| RSU | 7,000 | $267,470 | — |
| RSU | 4,920 | $187,993 | — |
| RSU | 2,460 | $93,997 | — |
| Option | 58,000 | — | $20.46 |
| Option | 14,761 | — | $22.40 |
| Option | 33,855 | — | $8.93 |
| Option | 820 | — | $27.50 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Travere Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
27 Form 4 lines since the FY2025 proxy (filed April 6, 2026)current to 2026-11-10 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-09-17 | Exercise or conversion | 10b5-1 | 8,282 | $22.40 | 125,348 |
| 2026-09-17 | Sale | 10b5-1 | 8,282 | $65.07 | 117,066 |
| 2026-09-17 | Exercise or conversion derivative | 10b5-1 | 8,282 | $0.00 | 44,837 |
| 2026-09-16 | Exercise or conversion | 10b5-1 | 17,717 | $26.88 | 289,783 |
| 2026-09-16 | Exercise or conversion | 10b5-1 | 100,000 | $11.25 | 217,066 |
| 2026-09-16 | Sale | 10b5-1 | 79,113 | $63.65 | 117,066 |
| 2026-09-16 | Exercise or conversion derivative | 10b5-1 | 100,000 | $0.00 | 0 |
| 2026-09-16 | Sale | 10b5-1 | 93,604 | $63.25 | 196,179 |
The 8 most recent of 27 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments Travere Therapeutics discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Death | — | $0 | — | $340,423 |
| Involuntary termination without cause | $795,000 | $2,705,139 | $37,013 | $3,612,575 |
| Change in control and involuntary termination | $1,192,500 | $5,062,002 | $55,519 | $6,385,444 |
| Disability | $530,000 | $2,705,139 | $37,013 | $3,612,575 |
Per the Potential Payments Upon Termination or Change in Control table in Travere Therapeutics, Inc.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
Travere Therapeutics’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Eric Dube | President, Chief Executive Officer and Director | $8,457,151 |
| Jula Inrig | Chief Medical Officer | $3,041,632 |
| Peter Heerma · this page | Chief Commercial Officer | $2,261,751 |
| William Rote | Chief Research Officer | $2,256,465 |
| Christopher Cline | Chief Financial Officer | $2,250,914 |
Peter Heerma's compensation dossier, Travere Therapeutics
You have read Peter Heerma's totals and holdings. The dossier adds each equity grant Travere Therapeutics disclosed for Peter Heerma and Travere Therapeutics's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Travere Therapeutics compensation record
free company briefThis page is one person within Travere Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Travere Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Travere Therapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Travere Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order TVTX
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.